| Validation of a Gene Expression Signature for Assessment of Lymph Node Metastasis in Oral Squamous Cell Carcinoma. | |
| | |
MedLine Citation:
|
PMID: 23045589 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSECurrent assessment of lymph node metastasis in patients with head and neck squamous cell carcinoma is not accurate enough to prevent overtreatment. The aim of this study was validation of a gene expression signature for distinguishing metastasizing (N+) from nonmetastasizing (N0) squamous cell carcinoma of the oral cavity (OSCC) and oropharynx (OPSCC) in a large multicenter cohort, using a diagnostic DNA microarray in a Clinical Laboratory Improvement Amendments/International Organization for Standardization-approved laboratory. METHODSA multigene signature, previously reported as predictive for the presence of lymph node metastases in OSCC and OPSCC, was first re-evaluated and trained on 94 samples using generic, whole-genome, DNA microarrays. Signature genes were then transferred to a dedicated diagnostic microarray using the same technology platform. Additional samples (n = 222) were collected from all head and neck oncologic centers in the Netherlands and analyzed with the diagnostic microarray. Human papillomavirus status was determined by real-time quantitative polymerase chain reaction.ResultsThe negative predictive value (NPV) of the diagnostic signature on the entire validation cohort (n = 222) was 72%. The signature performed well on the most relevant subset of early-stage (cT1-T2N0) OSCC (n = 101), with an NPV of 89%. CONCLUSIONCombining current clinical assessment with the expression signature would decrease the rate of undetected nodal metastases from 28% to 11% in early-stage OSCC. This should be sufficient to enable clinicians to refrain from elective neck treatment. A new clinical decision model that incorporates the expression signature is therefore proposed for testing in a prospective study, which could substantially improve treatment for this group of patients. |
| | |
Authors:
|
Sander R van Hooff; Frank K J Leusink; Paul Roepman; Robert J Baatenburg de Jong; Ernst-Jan M Speel; Michiel W M van den Brekel; Marie-Louise F van Velthuysen; Paul J van Diest; Robert J J van Es; Matthias A W Merkx; J Alain Kummer; C René Leemans; Ed Schuuring; Johannes A Langendijk; Martin Lacko; Maria J De Herdt; Jeroen C Jansen; Ruud H Brakenhoff; Piet J Slootweg; Robert P Takes; Frank C P Holstege |
Related Documents
:
|
1449109 - A phase ii clinical trial evaluating the use of two sequential, four-drug combination c... 22181559 - Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma. 7062419 - Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chlor... 2300379 - Salvage chemotherapy for breast cancer patients treated with adjuvant adriamycin-contai... 7535609 - Combined therapy for angioimmunoproliferative lesions. 7225999 - Metastatic sarcomas: chemotherapy with adriamycin, cyclophosphamide, and methotrexate a... 21071389 - Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and... 16421419 - Optimox1: a randomized study of folfox4 or folfox7 with oxaliplatin in a stop-and-go fa... 2981619 - Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (c... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-8 |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: - ISSN: 1527-7755 ISO Abbreviation: J. Clin. Oncol. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Frank K.J. Leusink, Robert J.J. van Es, Paul J. van Diest, Sander R. van Hooff, and Frank C.P. Holstege, University Medical Center Utrecht, Utrecht; Paul Roepman, Agendia; Michiel W.M. van den Brekel, Marie-Louise F. van Velthuysen, Netherlands Cancer Institute; C. René Leemans and Ruud H. Brakenhoff, Vrije Universiteit Medical Center, Amsterdam; Robert P. Takes, Matthias A.W. Merkx, Piet J. Slootweg, Radboud University Nijmegen Medical Center, Nijmegen; Robert J. Baatenburg de Jong, Maria J. De Herdt, Erasmus Medical Center, Rotterdam; Martin Lacko and Ernst-Jan M. Speel, Maastricht University Medical Center, Maastricht; Ed Schuuring and Johannes A. Langendijk, University Medical Center Groningen, Groningen; J. Alain Kummer, Saint Antonius Hospital, Nieuwegein; and Jeroen C. Jansen, Leiden University Medical Center, Leiden, the Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen...
Next Document: Mammostrat as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tam...